Assembly biosciences updates pipeline strategy, focusing on finite and curative therapies for chronic hepatitis b virus infection

- prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel targets - extends cash runway into 2023 - company to host conference call today at 5:00 p.m. et/2:00 p.m. pt
ASMB Ratings Summary
ASMB Quant Ranking